Navigating endophytic research for next-generation therapeutics /
Navigating Endophytic Research for Next-Generation Therapeutics explores the evolving field of endophytic fungal research and applications in combating diseases, addressing environmental challenges, and in shaping the future of therapeutics. The book starts off with a discussion on the biodiversity...
| Corporate Author: | |
|---|---|
| Other Authors: | , , , |
| Format: | eBook |
| Language: | English |
| Published: |
[Place of publication not identified] :
Academic Press,
2025.
|
| Series: | Developments in Applied Microbiology and Biotechnology
|
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
Table of Contents:
- Front Cover
- Navigating Endophytic Research for Next-Generation Therapeutics
- Navigating Endophytic Research for Next-Generation Therapeutics
- Copyright
- Contents
- Contributors
- About the editors
- Preface
- Acknowledgments
- Introduction
- 1
- Bioprospecting ethnopharmacological plants for endophytic fungal drug discovery
- 1. Introduction
- 2. Integration of ethnopharmacology and endophytic fungi for drug discovery
- 3. Fungal endophytes and drug discovery
- 3.1 Anticancer
- 3.2 Antioxidant
- 3.3 Antimicrobial
- 3.4 Antiinflammatory
- 4. Conclusion
- References
- 2
- Endophytic fungi in Himalayan medicinal plants: isolation procedures, diversity, and therapeutic applications
- 1. Introduction
- 2. Fungal endophytes
- 2.1 Root endophytes
- 3. Dark septate endophytes
- 4. Isolation of endophytic fungi
- 5. Fungal secondary metabolites
- 6. Beneficial fungal endophytes associated with some Himalayan plant species
- 6.1 Taxus wallichiana zucc
- 6.2 Betula utilis D. Don
- 6.3 Podophyllum hexandrum royle
- 6.4 Bacopa monnieri linn
- 6.5 Berberis aristata DC
- 6.6 Picrorhiza kurroa royle ex Benth
- 6.7 Ocimum sanctum linn
- 7. Conclusion
- References
- 3
- Pharmaceutical applications of endophytic fungi: current successes and future prospects
- 1. Introduction
- 2. Endophytic fungi: A rich hoard of pharmaceuticals
- 2.1 Paclitaxel
- 2.2 Camptothecin
- 2.3 Podophyllotoxin
- 2.4 Vinca alkaloids
- 3. Recent advances in pharmaceutical applications of endophytic fungi
- 3.1 Yield improvement
- 3.1.1 Bioprocess optimization
- 3.1.2 Mutagenesis
- 3.1.3 Elicitor stimulation
- 3.1.4 Coculturing
- 3.1.5 Metabolic engineering
- 3.2 Microbiome interaction
- 3.3 Multiomics approach
- 3.4 Genome mining
- 4. Challenges
- 5. Conclusion and future prospects
- References.
- 2. Endophytic fungi as a source of natural bioactive product
- 3. Endophytic fungi from medicinal plants
- 4. Mechanism of diabetes and obesity induction
- 5. Endophytic fungi as a potential source of antidiabetic agents
- 6. Endophytic fungi as a potential source of antiobesity agents
- 7. Conclusion
- References
- 9
- Antioxidant and antiinflammatory endophytic fungal compounds for chronic diseases
- 1. Introduction
- 2. Bioactive compounds from endophytic fungi
- 3. Antioxidant properties of endophytic fungi
- 4. Lead compounds produced by endophytic fungi with antioxidant properties
- 5. Lead compounds produced by endophytic fungi with antiinflammatory properties
- 6. Conclusion
- References
- 10
- Endophytic fungi as sources of cardiovascular drug leads
- 1. Introduction
- 2. Cardiovascular health
- 3. Exploring endophytes for cardiovascular drugs
- 4. Fungal metabolites
- 4.1 Aconitine
- 4.2 Berberine
- 4.3 Capsaicin
- 4.4 Vincamine
- 4.5 Isofraxidin
- 4.6 Kaempferol
- 4.7 Quercetin
- 4.8 Silymarin
- 4.9 Bilobalide and ginkgolides
- 4.10 Tanshinones
- 4.11 Forskolin (Coleonol)
- 4.12 Digoxin
- 4.13 Salidroside and p-tyrosol
- 4.14 Lovastatin
- 5. Mechanisms of action
- 5.1 Cardioprotective mechanisms
- 5.2 Antihypertensive mechanisms
- 5.3 Vasodilatory effects
- 5.4 Cholesterol-lowering mechanisms
- 5.5 Endothelial function improvement
- 6. Case studies: Cardiovascular drugs from endophytes
- 6.1 Detailed examination of specific drugs derived from endophytic sources
- 6.2 Taxol (paclitaxel)
- 6.3 Camptothecin
- 6.4 Ergot alkaloids
- 6.5 Vinblastine and vincristine
- 6.6 Artemisinin
- 6.7 Podophyllotoxin
- 6.8 Quinine
- 6.9 Statins (lovastatin)
- 7. Pharmacological properties and efficiency for cardiovascular disease management
- 7.1 Angiotensin-converting enzyme inhibitors.
- 7.2 Angiotensin II receptor blockers
- 7.3 Beta-blockers
- 7.4 Calcium channel blockers
- 7.5 Statins
- 7.6 Antiplatelet agents
- 7.7 Diuretics
- 8. Challenges and future perspectives
- 8.1 Challenges in developing cardiovascular drugs from endophytic sources
- 8.1.1 Identification of bioactive compounds
- 8.1.2 Bioavailability and pharmacokinetics
- 8.1.3 Toxicity assessment
- 8.1.4 Lack of standardization
- 8.1.5 Preclinical models and translational research
- 8.1.6 Regulatory hurdles
- 8.1.7 Commercialization and scale-up
- 8.2 Strategy: Investigate cost-effective production methods, such as fermentation processes, and collaborate with industry part ...
- 8.2.1 Potential solutions and strategies for overcoming obstacles
- 8.2.2 Identification and characterization of endophytes
- 8.2.3 Optimization of fermentation conditions
- 8.2.4 Scale-up of production
- 8.2.5 Isolation and purification
- 8.2.6 Bioassay-guided fractionation
- 8.2.7 Synthetic biology approaches
- 8.2.8 Collaboration and interdisciplinary research
- 8.2.9 Regulatory compliance
- 8.2.10 Investment in research and development
- 9. Research opportunities
- 9.1 Identification of novel compounds
- 9.2 Mechanistic studies
- 9.3 Optimization of production
- 9.4 Bioavailability and pharmacokinetics
- 9.5 Safety and toxicology studies
- 9.6 Clinical trials and translational research
- 9.7 Integration of multidisciplinary approaches
- 10. Conclusion
- References
- 11
- Commercialization of endophytic fungus-derived therapeutics: Opportunities and challenges
- 1. Introduction
- 2. Fungal endophytes in drug discovery and commercialization
- 3. Bioprospecting for endophytic fungal-derived compounds
- 4. Comparative advantages of endophytic fungi over other sources
- 5. Opportunities in drug development for fungal-derived therapeutics.
- 5.1 Synergy of endophytic fungi with existing pharmaceuticals
- 6. Challenges in commercialization of fungal endophyte-derived compounds
- 6.1 Case studies of successful commercialization of endophytic fungal-derived therapeutics
- 7. Overcoming hurdles: Collaborative approaches
- 7.1 Government initiatives and funding support
- 7.2 Ethical and social considerations in the commercialization of natural products
- 8. Conclusion
- 9. Future of endophytic fungal-derived therapeutics
- References
- 12
- Clinical trials and commercialization of endophytic fungal-derived therapeutics
- 1. Introduction
- 2. Endophytic fungi: Unveiling promising therapeutic frontiers
- 3. Drug development: Preclinical therapeutic research
- 3.1 Unraveling bioactive compounds: Isolation and characterization
- 3.2 Discovering biological potentials: Compound screening
- 3.3 Virtual assessment: Pharmacokinetics and toxicity evaluation
- 3.4 Commercial cultivation system
- 3.5 Animal model investigations: Assessing biological responses
- 4. Clinical trials: Testing remarkable therapeutics
- 5. Commercialization: Strategies for bringing innovations to market
- 6. Final thoughts: Insights and future outlook
- References
- 13
- Leveraging endophytic fungi and multiomics integration for targeted drug discovery
- 1. Introduction
- 2. Endophytic fungi: A source of bioactive metabolites
- 3. Biological activity of fungal secondary metabolites
- 4. Multiomics approaches in endophytic fungi research
- 5. Role of genomics and metagenomics approaches in endophytic fungi research
- 6. Role of transcriptomics approach in endophytic fungi research
- 7. Role of proteomics approach in endophytic fungi research
- 8. Role of metabolomics approach in endophytic fungi research
- 9. Strategies for activating silent gene clusters
- 10. Genetic manipulations.